.png)
Diabetes Devices And Drugs Market By Device (diabetes Monitoring And Diagnostic Devices, Insulin Delivery Devices) And Therapy (insulin, Oral Anti-diabetes Drugs Class, Non-insulin Injectable Anti-diabetes Drugs) - Global Industry Analysis And Forecast To 2023
Published On : June 2022 Pages : 190 Category: Medical Devices Report Code : HC061019
SEGMENTS & REGIONS:
- By Device: diabetes Monitoring And Diagnostic Devices, Insulin Delivery Devices
- And Therapy: insulin, Oral Anti-diabetes Drugs Class, Non-insulin Injectable Anti-diabetes Drugs
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Industry Outlook and Trend Analysis
The Diabetes Devices and Drugs Market was worth USD 32.82 billion in 2017 and is expected to reach approximately USD 58.97 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 6.74% during the forecast period. Diabetes mellitus, frequently eluded as diabetes, is an unending condition that outcomes when there are high levels of glucose in the blood. High blood glucose levels happen when our body cannot deliver any or enough of the hormone insulin or utilize it viably. Insulin is created in the pancreas and is a basic hormone for transporting glucose from our circulation system into the body cells where it gets changed over into vitality. The absence of insulin or the powerlessness of the cells to react to insulin prompts large amounts of blood glucose, or hyperglycaemia, which causes diabetes. If diabetes is undiscovered and treatment for it is not taken accurately, it prompts harm of other body organs and improvement of dangerous wellbeing inconveniences, for example, neuropathy, cardiovascular infection, nephropathy and eye ailment, prompting retinopathy and visual impairment.
Drivers & Restrains
The essential main thrust of the worldwide diabetes devices and drugs market is the developing commonness of diabetes in the world. Raising diabetic populace brings about expanding interest for diabetic care. Aside from a variety of existing medications and devices, broad research and development ventures for new diabetic investigative and treatment techniques has given the business a lift. Different factors, for example, mechanical advancements and aggressive valuing procedures by new members in the market add a positive acceleration. Untapped areas, for example, investigation of non-invasive techniques for diabetes administration are certain to help the development of the diabetes devices and drugs market. However, the fundamental requirements that happen are mind-boggling expense of finding and treatment, poor repayment strategies, and troublesome section for new players into the diabetes devices and diabetes drugs market.
Regional Outlook and Trend Analysis
North America held the biggest share of the market in 2017. This is credited to developing economy and propelled medicinal services framework combined with familiarity with populace in regards to the treatment of diabetes and related illnesses. In North America and Europe the glucose monitoring device portion of diabetes device and drugs market contributes the greatest offer. Asia Pacific may demonstrate a promising business sector for the diabetes device business as a result of expanding populace and expanding social insurance offices and developing economy. Also the Asia pacific, South America districts are concentrating on expanding diabetes facilities which will drive the market amid conjecture period.
Competitive Insights
The leading players in the market are Novo Nordisk A/S, AstraZeneca plc, Sanofi, Merck Inc., Takeda Pharmaceutical Company Limited and others. Many Key players are depending on methods, for example, agreements & joint ventures, collaborations, and advancements to build the visibility of their products and fortify their product portfolios.
The Diabetes Devices and Drugs Market is segmented as follows-
By Devices:
- Diabetes Monitoring and diagnostic devices
- Analog glucose meter
- Glucose Test strips
- Lancets and Lancing devices
- Continuous glucose monitoring devices
- Others
- Insulin Delivery Devices
- Insulin Syringes
- Insulin Pens
- Insulin Pumps
- Insulin Injectors
By Therapy:
- Insulin
- Short-acting insulin derivatives
- Intermediate-acting insulin derivatives
- Long-acting insulin derivatives
- Rapid-acting insulin derivatives
- Premixed insulin derivatives
- Oral anti-diabetes drugs class
- Sulphonylureas
- Biguanides
- Meglitinides
- Thiazolidinediones
- Alpha-glucosidase inhibitors
- DPP-4 inhibitors
- SGLT-2 inhibitors
- Non-insulin injectable anti-diabetes drugs
- GLP-1 analogs
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- South Africa
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2023?
- What will be the industry market growth from 2017 to 2023?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Diabetes Devices and Drugs Market, By Device, Estimates and Forecast, 2014-2023 ($Million)
· Diabetes Monitoring and diagnostic devices
o Analog glucose meter
o Glucose Test strips
o Lancets and Lancing devices
o Continuous glucose monitoring devices
o Others
· Insulin Delivery Devices
o Insulin Syringes
o Insulin Pens
o Insulin Pumps
o Insulin Injectors
· Diabetes Devices and Drugs Market, By Therapy, Estimates and Forecast, 2014-2023 ($Million)
· Insulin
o Short-acting insulin derivatives
o Intermediate-acting insulin derivatives
o Long-acting insulin derivatives
o Rapid-acting insulin derivatives
o Premixed insulin derivatives
· Oral anti-diabetes drugs class
o Sulphonylureas
o Biguanides
o Meglitinides
o Thiazolidinediones
o Alpha-glucosidase inhibitors
o DPP-4 inhibitors
o SGLT-2 inhibitors
· Non-insulin injectable anti-diabetes drugs
o GLP-1 analogs
· Diabetes Devices and Drugs Market, By Region, Estimates and Forecast, 2014-2023 ($Million)
· North America
§ North America Diabetes Devices and Drugs Market, By Country
o U.S. Diabetes Devices and Drugs Market
o Canada Diabetes Devices and Drugs Market
o Mexico Diabetes Devices and Drugs Market
· Europe
§ Europe Diabetes Devices and Drugs Market, By Country
o Germany Diabetes Devices and Drugs Market
o UK Diabetes Devices and Drugs Market
o France Diabetes Devices and Drugs Market
o Russia Diabetes Devices and Drugs Market
o Italy Diabetes Devices and Drugs Market
o Rest of Europe Diabetes Devices and Drugs Market
· Asia-Pacific
§ Asia-Pacific Diabetes Devices and Drugs Market, By Country
o China Diabetes Devices and Drugs Market
o Japan Diabetes Devices and Drugs Market
o South Korea Diabetes Devices and Drugs Market
o India Diabetes Devices and Drugs Market
o Southeast Asia Diabetes Devices and Drugs Market
o Rest of Asia-Pacific Diabetes Devices and Drugs Market
· South America
§ South America Diabetes Devices and Drugs Market
o Brazil Diabetes Devices and Drugs Market
o Argentina Diabetes Devices and Drugs Market
o Columbia Diabetes Devices and Drugs Market
o South Africa Diabetes Devices and Drugs Market
o Rest of South America Diabetes Devices and Drugs Market
· Middle East and Africa
§ Middle East and Africa Diabetes Devices and Drugs Market
o Saudi Arabia Diabetes Devices and Drugs Market
o UAE Diabetes Devices and Drugs Market
o Egypt Diabetes Devices and Drugs Market
o Nigeria Diabetes Devices and Drugs Market
o South Africa Diabetes Devices and Drugs Market
o Rest of MEA Diabetes Devices and Drugs Market
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market States and Outlook (2017-2023)
4.1.2. Canada Market States and Outlook (2017-2023)
4.1.3. Mexico Market States and Outlook (2017-2023)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market States and Outlook (2017-2023)
4.2.2. France Market States and Outlook (2017-2023)
4.2.3. UK Market States and Outlook (2017-2023)
4.2.4. Russia Market States and Outlook (2017-2023)
4.2.5. Italy Market States and Outlook (2017-2023)
4.2.6. Rest of Europe Market States and Outlook (2017-2023)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market States and Outlook (2017-2023)
4.3.2. Japan Market States and Outlook (2017-2023)
4.3.3. Korea Market States and Outlook (2017-2023)
4.3.4. India Market States and Outlook (2017-2023)
4.3.5. Rest of Asia-Pacific Market States and Outlook (2017-2023)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market States and Outlook (2017-2023)
4.4.2. Argentina Market States and Outlook (2017-2023)
4.4.3. Columbia Market States and Outlook (2017-2023)
4.4.4. Rest of South America Market States and Outlook (2017-2023)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market States and Outlook (2017-2023)
4.5.2. UAE Market States and Outlook (2017-2023)
4.5.3. Egypt Market States and Outlook (2017-2023)
4.5.4. Nigeria Market States and Outlook (2017-2023)
4.5.5. South Africa Market States and Outlook (2017-2023)
4.5.6. Rest of MEA Market States and Outlook (2017-2023)
5. Diabetes Devices and Drugs Market, By Device
5.1. Introduction
5.2. Global Diabetes Devices and Drugs Sales, Revenue and Market Share by Device (2017-2027)
5.2.1. Global Diabetes Devices and Drugs Sales and Sales Share by Device (2017-2027)
5.2.2. Global Diabetes Devices and Drugs Revenue and Revenue Share by Device (2017-2027)
5.3. Diabetes Monitoring and diagnostic devices
5.3.1. Global Diabetes Monitoring and diagnostic devices Sales and Growth Rate (2017-2027)
5.3.2. Global Diabetes Monitoring and diagnostic devices Sales and Growth Rate By Type (2017-2027)
5.3.3. Analog glucose meter
5.3.3.1. Global Analog glucose meter Sales and Growth Rate (2017-2027)
5.3.4. Glucose Test strips
5.3.4.1. Global Glucose Test strips Sales and Growth Rate (2017-2027)
5.3.5. Lancets and Lancing devices
5.3.5.1. Global Lancets and Lancing devices Sales and Growth Rate (2017-2027)
5.3.6. Continuous glucose monitoring devices
5.3.6.1. Global Continuous glucose monitoring devices Sales and Growth Rate (2017-2027)
5.3.7. Others
5.3.7.1. Global Others Sales and Growth Rate (2017-2027)
5.4. Insulin Delivery Devices
5.4.1. Global Insulin Delivery Devices Sales and Growth Rate (2017-2027)
5.4.2. Global Insulin Delivery Devices Sales and Growth Rate By Type (2017-2027)
5.4.3. Insulin Syringes
5.4.3.1. Global Insulin Syringes Sales and Growth Rate (2017-2027)
5.4.4. Insulin Pens
5.4.4.1. Global Insulin Pens Sales and Growth Rate (2017-2027)
5.4.5. Insulin Pumps
5.4.5.1. Global Insulin Pumps Sales and Growth Rate (2017-2027)
5.4.6. Insulin Injectors
5.4.6.1. Global Insulin Injectors Sales and Growth Rate (2017-2027)
6. Diabetes Devices and Drugs Market, By Therapy
6.1. Introduction
6.2. Global Diabetes Devices and Drugs Sales, Revenue and Market Share by Therapy (2017-2027)
6.2.1. Global Diabetes Devices and Drugs Sales and Sales Share by Therapy (2017-2027)
6.2.2. Global Diabetes Devices and Drugs Revenue and Revenue Share by Therapy (2017-2027)
6.3. Insulin
6.3.1. Global Insulin Sales and Growth Rate (2017-2027)
6.3.2. Global Insulin Sales and Growth Rate By Type (2017-2027)
6.3.3. Short-acting insulin derivatives
6.3.3.1. Global Short-acting insulin derivatives Sales and Growth Rate (2017-2027)
6.3.4. Intermediate-acting insulin derivatives
6.3.4.1. Global Intermediate-acting insulin derivatives Sales and Growth Rate (2017-2027)
6.3.5. Long-acting insulin derivatives
6.3.5.1. Global Long-acting insulin derivatives Sales and Growth Rate (2017-2027)
6.3.6. Rapid-acting insulin derivatives
6.3.6.1. Global Rapid-acting insulin derivatives Sales and Growth Rate (2017-2027)
6.3.7. Premixed insulin derivatives
6.3.7.1. Global Premixed insulin derivatives Sales and Growth Rate (2017-2027)
6.4. Oral anti-diabetes drugs class
6.4.1. Global Oral anti-diabetes drugs class Sales and Growth Rate (2017-2027)
6.4.2. Global Oral anti-diabetes drugs class Sales and Growth Rate By Type (2017-2027)
6.4.3. Sulphonylureas
6.4.3.1. Global Sulphonylureas Sales and Growth Rate (2017-2027)
6.4.4. Biguanides
6.4.4.1. Global Biguanides Sales and Growth Rate (2017-2027)
6.4.5. Meglitinides
6.4.5.1. Global Meglitinides Sales and Growth Rate (2017-2027)
6.4.6. Thiazolidinediones
6.4.6.1. Global Thiazolidinediones Sales and Growth Rate (2017-2027)
6.4.7. Alpha-glucosidase inhibitors
6.4.7.1. Global Alpha-glucosidase inhibitors Sales and Growth Rate (2017-2027)
6.4.8. DPP-4 inhibitors
6.4.8.1. Global DPP-4 inhibitors Sales and Growth Rate (2017-2027)
6.4.9. SGLT-2 inhibitors
6.4.9.1. Global SGLT-2 inhibitors Sales and Growth Rate (2017-2027)
6.5. Non-insulin injectable anti-diabetes drugs
6.5.1. Global Non-insulin injectable anti-diabetes drugs Sales and Growth Rate (2017-2027)
6.5.2. Global Non-insulin injectable anti-diabetes drugs Sales and Growth Rate By Type (2017-2027)
6.5.3. GLP-1 analogs
6.5.3.1. Global GLP-1 analogs Sales and Growth Rate (2017-2027)
7. Diabetes Devices and Drugs Market, By Region
7.1. Introduction
7.2. Global Diabetes Devices and Drugs Sales, Revenue and Market Share by Regions
7.2.1. Global Diabetes Devices and Drugs Sales by Regions (2017-2027)
7.2.2. Global Diabetes Devices and Drugs Revenue by Regions (2017-2027)
7.3. North America Diabetes Devices and Drugs by Countries
7.3.1. North America Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.3.2. North America Diabetes Devices and Drugs Revenue and Growth Rate (2017-2027)
7.3.3. North America Diabetes Devices and Drugs Sales by Countries (2017-2027)
7.3.4. North America Diabetes Devices and Drugs Revenue (Million USD) by Countries (2017-2027)
7.3.5. U.S.
7.3.5.1. United States Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.3.5.2. United States Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.6. Canada
7.3.6.1. Canada Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.3.6.2. Canada Diabetes Devices and Drugs Sales (Millions USD) and Growth Rate (2017-2027)
7.3.7. Mexico
7.3.7.1. Mexico Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.3.7.2. Mexico Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Diabetes Devices and Drugs by Countries
7.4.1. Europe Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.4.2. Europe Diabetes Devices and Drugs Revenue and Growth Rate (2017-2027)
7.4.3. Europe Diabetes Devices and Drugs Sales by Countries (2017-2027)
7.4.4. Europe Diabetes Devices and Drugs Revenue (Million USD) by Countries (2017-2027)
7.4.5. Germany
7.4.5.1. Germany Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.4.5.2. Germany Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. UK
7.4.6.1. UK Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.4.6.2. UK Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. France
7.4.7.1. France Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.4.7.2. France Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Russia
7.4.8.1. Russia Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.4.8.2. Russia Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.9. Italy
7.4.9.1. Italy Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.4.9.2. Italy Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.10. Rest of Europe
7.4.10.1. Rest of Europe Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.4.10.2. Rest of Europe Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific
7.5.1. Asia-Pacific Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Diabetes Devices and Drugs Revenue and Growth Rate (2017-2027)
7.5.3. Asia-Pacific Diabetes Devices and Drugs Sales by Countries (2017-2027)
7.5.4. Asia-Pacific Diabetes Devices and Drugs Revenue (Million USD) by Countries (2017-2027)
7.5.5. China
7.5.5.1. China Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.5.5.2. China Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. Japan
7.5.6.1. Japan Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.5.6.2. Japan Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6.3.
7.5.7. Korea
7.5.7.1. Korea Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.5.7.2. Korea Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. India
7.5.8.1. India Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.5.8.2. India Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.9. Southeast Asia
7.5.9.1. Southeast Asia Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.5.9.2. Southeast Asia Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.10. Rest of Asia-Pacific
7.5.10.1. Rest of Asia-Pacific Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.5.10.2. Rest of Asia-Pacific Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America
7.6.1. South America Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.6.2. South America Diabetes Devices and Drugs Revenue and Growth Rate (2017-2027)
7.6.3. South America Diabetes Devices and Drugs Sales by Countries (2017-2027)
7.6.4. South America Diabetes Devices and Drugs Revenue (Million USD) by Countries (2017-2027)
7.6.5. Brazil
7.6.5.1. Brazil Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.6.5.2. Brazil Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Argentina
7.6.6.1. Argentina Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.6.6.2. Argentina Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.7. Columbia
7.6.7.1. Columbia Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.6.7.2. Columbia Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.8. Rest of South America
7.6.8.1. Rest of South America Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.6.8.2. Rest of South America Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa
7.7.1. Middle East and Africa Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Diabetes Devices and Drugs Revenue and Growth Rate (2017-2027)
7.7.3. Middle East and Africa Diabetes Devices and Drugs Sales by Countries (2017-2027)
7.7.4. Middle East and Africa Diabetes Devices and Drugs Revenue (Million USD) by Countries (2017-2027)
7.7.5. Saudi Arabia
7.7.5.1. Saudi Arabia Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.7.5.2. Saudi Arabia Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. United Arab Emirates
7.7.6.1. United Arab Emirates Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.7.6.2. United Arab Emirates Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. Egypt
7.7.7.1. Egypt Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.7.7.2. Egypt Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Nigeria
7.7.8.1. Nigeria Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.7.8.2. Nigeria Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. South Africa
7.7.9.1. South Africa Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.7.9.2. South Africa Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.10. Rest of Middle East and Africa
7.7.10.1. Rest of Middle East and Africa Diabetes Devices and Drugs Sales and Growth Rate (2017-2027)
7.7.10.2. Rest of Middle East and Africa Diabetes Devices and Drugs Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Medtronic
8.1.1. Business Overview
8.1.2. Product Portfolio
8.1.3. Strategic Developments
8.1.4. Sales, Revenue and Market Share
8.2. Novo Nordisk A/S
8.2.1. Business Overview
8.2.2. Product Portfolio
8.2.3. Strategic Developments
8.2.4. Sales, Revenue and Market Share
8.3. Sanofi
8.3.1. Business Overview
8.3.2. Product Portfolio
8.3.3. Strategic Developments
8.3.4. Sales, Revenue and Market Share
8.4. Eli Lilly and Company
8.4.1. Business Overview
8.4.2. Product Portfolio
8.4.3. Strategic Developments
8.4.4. Sales, Revenue and Market Share
8.5. F. Hoffmann-La Roche Ltd.
8.5.1. Business Overview
8.5.2. Product Portfolio
8.5.3. Strategic Developments
8.5.4. Sales, Revenue and Market Share
8.6. Becton, Dickinson and Company
8.6.1. Business Overview
8.6.2. Product Portfolio
8.6.3. Strategic Developments
8.6.4. Sales, Revenue and Market Share
8.7. Tandem Diabetes Care, Inc.
8.7.1. Business Overview
8.7.2. Product Portfolio
8.7.3. Strategic Developments
8.7.4. Sales, Revenue and Market Share
8.8. Abbott Laboratories
8.8.1. Business Overview
8.8.2. Product Portfolio
8.8.3. Strategic Developments
8.8.4. Sales, Revenue and Market Share
8.9. Cellnovo
8.9.1. Business Overview
8.9.2. Product Portfolio
8.9.3. Strategic Developments
8.9.4. Sales, Revenue and Market Share
8.10. Insulet Corporation
8.10.1. Business Overview
8.10.2. Product Portfolio
8.10.3. Strategic Developments
8.10.4. Sales, Revenue and Market Share
9. Global Diabetes Devices and Drugs Market Competition, by Manufacturer
9.1. Global Diabetes Devices and Drugs Sales and Market Share by Manufacturer (2017-2017)
9.2. Global Diabetes Devices and Drugs Revenue and Market Share by Manufacturer (2017-2017)
9.3. Global Diabetes Devices and Drugs Price by Manufacturer (2017-2017)
9.4. Top 5 Diabetes Devices and Drugs Manufacturer Market Share
9.5. Market Competition Trend
10. Diabetes Devices and Drugs Market Forecast (2027-2023)
10.1. Global Diabetes Devices and Drugs Sales, Revenue (Millions USD) and Growth Rate (2027-2023)
10.2. Diabetes Devices and Drugs Market Forecast by Regions (2027-2023)
10.2.1. North America Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.1.1. United States Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.1.2. Canada Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.1.3. Mexico Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.2. Europe Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.2.1. Germany Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.2.2. United Kingdom Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.2.3. France Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.2.4. Russia Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.2.5. Italy Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.2.6. Rest of the Europe Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.3. Asia-Pacific Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.3.1. China Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.3.2. Japan Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.3.3. Korea Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.3.4. India Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.3.5. Southeast Asia Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.3.6. Rest of Asia-Pacific Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.4. South America Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.4.1. Brazil Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.4.2. Argentina Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.4.3. Columbia Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.4.4. Rest of South America Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.5. Middle East and Africa Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.5.1. Saudi Arabia Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.5.2. UAE Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.5.3. Egypt Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.5.4. Nigeria Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.5.5. South Africa Diabetes Devices and Drugs Market Forecast (2027-2023)
10.2.5.6. Rest of MEA Diabetes Devices and Drugs Market Forecast (2027-2023)
10.3. Diabetes Devices and Drugs Market Forecast by Device (2027-2023)
10.3.1. Global Diabetes Devices and Drugs Sales Forecast by Device (2027-2023)
10.3.2. Global Diabetes Devices and Drugs Sales Market Share Forecast by Device (2027-2023)
10.4. Diabetes Devices and Drugs Market Forecast by Therapy (2027-2023)
10.4.1. Global Diabetes Devices and Drugs Sales Forecast by Therapy (2027-2023)
10.4.2. Global Diabetes Devices and Drugs Sales Market Share Forecast by Therapy (2027-2023)
List of Tables
*You can glance through the list of Tables and Figures when you view the sample copy of Diabetes Devices and Drugs Market.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|